Oricula Therapeutics
PrivateLast Round
Grant
Feb 2, 2016
Total Funding Raised
$2.18M
Company Overview
Oricula Therapeutics operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in February 2016.
Oricula Therapeutics is a biotechnology company that develops medications to protect hearing and balance from the damaging effects of ototoxic drugs and aging.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oricula Therapeutics Comparables
Compare Oricula Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sound Pharmaceuticals, Inc. | 83% | |
| Ting Therapeutics | 83% | |
| Otologic Pharmaceutics | 79% |
For institutional investors. Book with your work email.
Oricula Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 2, 2016 | ||||
| Grant | Apr 30, 2014 | ||||
| Angel | Apr 9, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oricula Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| National Institute on Deafness and Other Communication Disorders | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2026
Monthly visitors grew 105% MoM.
- Jan 20, 2026
Monthly visitors increased 58% MoM.
For institutional investors. Book with your work email.
Oricula Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oricula Therapeutics's valuation, stock price, and market status.
Is Oricula Therapeutics a public or private company?
Oricula Therapeutics is a private company.
What is the current stock price of Oricula Therapeutics?
Oricula Therapeutics is a private company, so its shares have no public market price. Caplight tracks Oricula Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oricula Therapeutics worth (valuation)?
Valuation information for Oricula Therapeutics is not publicly available.
Can I buy Oricula Therapeutics stock?
Oricula Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oricula Therapeutics's last funding round?
Oricula Therapeutics's most recent funding round was Grant on February 2, 2016.
Who are the main investors in Oricula Therapeutics?
Key investors in Oricula Therapeutics include National Institute of Allergy and Infectious Diseases, National Institute on Deafness and Other Communication Disorders.
Will Oricula Therapeutics IPO soon?
No public IPO plans have been announced for Oricula Therapeutics.
How can I track Oricula Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Oricula Therapeutics's shares on secondary markets.